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Incomplete discussion 
of bipolar disorder and 
comorbid substance use 
disorder 
Authors’ reply
Na raises two issues. Regarding the 
first issue, we agree that bipolar 
disorders in prison populations merit 
further discussion. The inclusion 
of bipolar disorder as a psychotic 
illness is based on the increasingly 
accepted view that bipolar disorder 
and schizophrenia-spectrum disorders 
share phenomenological, biological, 
and genetic overlap.1 In addition, for 
a diagnosis of type 1 bipolar disorder, 
a manic episode is necessary, which is 
typically psychotic in nature. However, 
our decision not to separate out bipolar 
disorder from the other psychoses was 
based on the difficulty of establishing 
this distinction in prisoners. Many 
prisoners have histories of drug 
misuse and also personality disorders 
in which mood instability (and in 
particular slightly elevated mood or 
hypomania, common in the rarer form 
of bipolar 2 disorder) is common and 
diagnoses require repeat examination 
and informant histories. Thus, most 
structured interviews administered in 
prevalence studies do not perform well 
to detect bipolar disorder.
Second, Na raises the important issue 
of comorbidities. We looked again at the 
23 studies reported in our review,2 and 
found that six reported on comorbidities 
between substance use disorders and 
severe mental illness (table). These 
comorbidities are common, and prison 
health should take these into account 
by joining up psychiatric and substance 
misuse services.
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Alcohol use 
disorders in 
people with 
affective disorder 
or major 
depression
Drug use 
disorders in 
people with 
affective disorder 
or major 
depression
Substance 
use disorders 
in people 
with major 
depression
Substance use 
disorders in 
people with 
psychosis 
Current or 1-year prevalence, %
Andreoli et al (2014)3 18·7% (men), 
60·0% (women)
2·7% (men), 
60·0% (women)
·· ··
Joshi et al (2014)4 22·2% 11·1% 33·3% ··
Mundt et al (2013)5 ·· ·· 22·8% ··
Naidoo and Mkize (2012)6 ·· ·· 30·3% 55·5% 
Zamzam and Hatta (2000)7 ·· ·· 61·9% ··
Lifetime prevalence, %
Andreoli et al (2014)3 40·7% (men), 
68·3% (women)
52·3% (men), 
68·3% (women)
·· ··
Assadi et al (2006)8 ·· ·· 82·5% 95·0%
Table: Prevalence of comorbid substance use disorders among prisoner populations with severe 
mental illness in low-income and middle-income countries
